CMS is considering substantial updates to its TAVR policies, including coverage for asymptomatic patients. Some stakeholders are excited, embracing the possibility of expanded indications and fewer restrictions. Others are concerned that the changes would be too much, too soon.

Anteris Technologies is known for its biomimetic transcatheter heart valve, the DurAVR THV System. The device is the first of its kind and has gained considerable attention as the TAVR market continues to grow.

The FTC argued that the $945M deal, first announced in 2024, was "anticompetitive." A federal judge agreed. 

A vulnerable heart patient required TAVR, but he faced an extremely high risk of coronary obstruction. Leaflet modification and snorkel stenting were not possible, so the group turned to a brand new treatment option: the VECTOR procedure.

TAVR has already transformed care for patients with severe aortic stenosis. Will it make a similar impact on the treatment of aortic regurgitation?

By tracking sex-related differences after TAVR, researchers hope to refine patient selection strategies and optimize care for both men and women.

Patients with this specific subtype of severe aortic stenosis, which can sometimes be challenging to diagnose, face a number of additional risks.

Chris Waddell, a medtech executive focused on various structural heart technologies, is leaving Abbott after several years to "recharge" and pursue a new opportunity.

Researchers tracked data from more than 400,00 patients, sharing their findings in JAMA Cardiology.

Postprocedural gradients can tell cardiologists a lot about a patient's long-term risk of structural valve deterioration.